Navigation Links
Emisphere to Host Business Strategy Conference Call on February 7
Date:1/31/2008

- CEO Michael V. Novinski to Discuss Plans for Company in 2008 and Beyond -

CEDAR KNOLLS, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that it will host a teleconference on Thursday, February 7, at 10:00 AM EST. President and Chief Executive Officer Michael V. Novinski will discuss the company's emerging business strategy. Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology.

A live Webcast of the conference call can be accessed through the company's web site at http://www.emisphere.com. The live conference call dial-in number is: 1-888-264-8952 (U.S. and Canada) or 1-913-312-0654 (International). In addition, an archive of the Webcast can be accessed through the same link; an audio replay of the call will be available following the conference call by calling 1-888-203-1112 (U.S. and Canada) or 1-719-457-0820 (International). The conference replay PIN is 871428. A slide deck will be available on the Emisphere web site at the time of the call.

"Emisphere's investor base is a valued resource," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc. "Our teleconference will provide investors with a better understanding of where we are taking the company and what opportunities lie ahead."

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its eligen(R) technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Web site is http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758) and for the quarter ended June 30, 2007, filed on August 7, 2007 (file No. 000-17758).


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
2. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
3. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
4. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. Medefield Announces New Appointments to North American Business Unit
8. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
9. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
10. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
11. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led ... grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The ... treating coronary artery disease (CAD). Lam is an assistant professor at the Department ...
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017 ... Biotech Venture Fund (MBVF), today announced positive results of ... the standard drug therapy regimen in patients with multidrug-resistant ... drug discovered by scientists at Sequella, Inc. ( ... Health. A total of 140 patients ...
(Date:3/24/2017)... 2017 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ... cancer vaccines, today announced participation at the following conferences: ... Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" ... New York, NY . Agenus will participate ... 9:40 am: Robert B. Stein , M.D., Ph.D., ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseq™ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):